Janux Therapeutics to present initial JANX011 Phase 1 data at virtual event
JANX•Janux Therapeutics will host a virtual event on Nov. 9, 2026, at 8:30 a.m. ET, where CEO David Campbell will present initial Phase 1 data for JANX011 in healthy volunteers.
1. Virtual event
The presentation will cover safety, pharmacokinetics and pharmacodynamics from the single-ascending-dose study, including implications for JANX011’s autoimmune disease development and the broader ARM platform.
